Nurix Therapeutics Statistics
Total Valuation
NRIX has a market cap or net worth of $2.48 billion. The enterprise value is $2.09 billion.
| Market Cap | 2.48B |
| Enterprise Value | 2.09B |
Important Dates
The last earnings date was Thursday, July 9, 2026, after market close.
| Earnings Date | Jul 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NRIX has 103.78 million shares outstanding. The number of shares has increased by 25.67% in one year.
| Current Share Class | 103.78M |
| Shares Outstanding | 103.78M |
| Shares Change (YoY) | +25.67% |
| Shares Change (QoQ) | +0.92% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 92.44% |
| Float | 82.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 67.38 |
| Forward PS | 13.62 |
| PB Ratio | 5.92 |
| P/TBV Ratio | 6.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 56.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.34, with a Debt / Equity ratio of 0.14.
| Current Ratio | 6.34 |
| Quick Ratio | 6.18 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -80.30% and return on invested capital (ROIC) is -47.01%.
| Return on Equity (ROE) | -80.30% |
| Return on Assets (ROA) | -40.06% |
| Return on Invested Capital (ROIC) | -47.01% |
| Return on Capital Employed (ROCE) | -77.92% |
| Weighted Average Cost of Capital (WACC) | 13.84% |
| Revenue Per Employee | $115,981 |
| Profits Per Employee | -$1.08M |
| Employee Count | 317 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -271,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +87.94% in the last 52 weeks. The beta is 1.80, so NRIX's price volatility has been higher than the market average.
| Beta (5Y) | 1.80 |
| 52-Week Price Change | +87.94% |
| 50-Day Moving Average | 18.65 |
| 200-Day Moving Average | 16.26 |
| Relative Strength Index (RSI) | 67.77 |
| Average Volume (20 Days) | 2,311,140 |
Short Selling Information
The latest short interest is 17.80 million, so 17.15% of the outstanding shares have been sold short.
| Short Interest | 17.80M |
| Short Previous Month | 20.02M |
| Short % of Shares Out | 17.15% |
| Short % of Float | 21.50% |
| Short Ratio (days to cover) | 4.72 |
Income Statement
In the last 12 months, NRIX had revenue of $36.77 million and -$341.35 million in losses. Loss per share was -$3.41.
| Revenue | 36.77M |
| Gross Profit | -304.17M |
| Operating Income | -361.18M |
| Pretax Income | -341.62M |
| Net Income | -341.35M |
| EBITDA | -353.18M |
| EBIT | -361.18M |
| Loss Per Share | -$3.41 |
Balance Sheet
The company has $443.53 million in cash and $58.14 million in debt, with a net cash position of $385.39 million or $3.71 per share.
| Cash & Cash Equivalents | 443.53M |
| Total Debt | 58.14M |
| Net Cash | 385.39M |
| Net Cash Per Share | $3.71 |
| Equity (Book Value) | 402.63M |
| Book Value Per Share | 3.88 |
| Working Capital | 384.46M |
Cash Flow
In the last 12 months, operating cash flow was -$293.70 million and capital expenditures -$10.82 million, giving a free cash flow of -$304.53 million.
| Operating Cash Flow | -293.70M |
| Capital Expenditures | -10.82M |
| Depreciation & Amortization | 8.00M |
| Net Borrowing | n/a |
| Free Cash Flow | -304.53M |
| FCF Per Share | -$2.93 |
Margins
| Gross Margin | n/a |
| Operating Margin | -982.37% |
| Pretax Margin | -929.18% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.67% |
| Shareholder Yield | -25.67% |
| Earnings Yield | -13.78% |
| FCF Yield | -12.29% |
Analyst Forecast
The average price target for NRIX is $32.50, which is 36.27% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.50 |
| Price Target Difference | 36.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 34.57% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NRIX has an Altman Z-Score of 1.62 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.62 |
| Piotroski F-Score | 1 |